Clene

Compare

1,103 Followers

CLNN Stock Chart & Stats

$10.00

-$0.20(-3.40%)

At close: Jan 08 4:00 PM EST

$10.00

-$0.20(-3.40%)

Day’s Range― - ―

52-Week Range$2.28 - $11.06

Previous CloseN/A

Volume48.08K

Average Volume (3M)123.85K

Market Cap

$100.70M

Enterprise Value$50.80M

Total Cash (Recent Filing)$7.29M

Total Debt (Recent Filing)$20.85M

Price to Earnings (P/E)―

Beta1.37

Next Earnings

Nov 11, 2025

EPS Estimate

-0.58

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.78

Shares Outstanding10,069,970

10 Day Avg. Volume69,732

30 Day Avg. Volume123,853

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.50

Enterprise Value/Revenue177.62

Enterprise Value/Gross Profit220.86

Enterprise Value/Ebitda-1.71

Forecast

1Y Price Target

$32.00

Price Target Upside220.00% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

ALS TreatmentClene's CNM-Au8 asset has the potential to play a significant role in the treatment of patients with ALS.

FDA FeedbackThe FDA expressed openness to considering other potential primary endpoints, including cognition, to evaluate broader treatment effects.

Multiple Sclerosis ResearchPositive clinical data for Clene’s CNM-Au8 in the treatment of Multiple Sclerosis was presented in a late-breaking session at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

Bears Say

Clene News

Clene’s CNM-Au8: A Promising Game-Changer in ALS Treatment with Buy Rating from Justin Walsh

Clene, the Consumer Defensive sector company, was revisited by a Wall Street analyst yesterday. Analyst Justin Walsh from...

9d ago

CLNN

Clene Enters Equity Distribution Agreement with Canaccord

The latest update is out from Clene ( ($CLNN) ). Clene Inc., a company in the biotechnology sector,...

14d ago

CLNN

Clene’s Promising Clinical Developments and Strategic Advancements Justify Buy Rating

Clene, the Consumer Defensive sector company, was revisited by a Wall Street analyst yesterday. Analyst Bruce Jackson from...

1M ago

CLNN

Buy Rating for Clene Driven by Promising CNM-Au8 Developments and FDA Support

JonesTrading analyst Justin Walsh has reiterated their bullish stance on CLNN stock, giving a Buy rating today. Justin...

1M ago

CLNN

Clene’s Promising Therapeutic Developments and Regulatory Progress Drive Buy Rating

Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Clene and keeping the price target at...

1M ago

CLNN

Clene Unveils Promising Clinical Data at ECTRIMS 2025

An announcement from Clene ( ($CLNN) ) is now available. On September 25, 2025, Clene announced new clinical...

1M ago

CLNN

Clene announces presentation of combined REPAIR-MS results

Clene (CLNN) announced the presentation of the combined REPAIR-MS results across relapsing MS and non-active progressive MS during...

1M ago

CLNN

Clene price target lowered to $31 from $33 at Benchmark

Benchmark lowered the firm’s price target on Clene (CLNN) to $31 from $33 and keeps a Buy rating...

2M ago

CLNN

Clene Expands Equity Distribution to Raise Capital

Clene ( ($CLNN) ) has issued an announcement. On April 28, 2025, Clene Inc. entered into an equity...

2M ago

CLNN

Clene files to sell 491,496 shares of common stock for holders

16:20 EDT Clene (CLNN) files to sell 491,496 shares of common stock for holders Published first on TheFly...

2M ago

CLNN

Clene’s CNM-Au8 Shows Promise in Parkinson’s Treatment, Justifying Buy Rating

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Clene, retaining the price target of $31.00....

2M ago

CLNN

Clene presents preclinical data supporting CNM-Au8 for Parkinson’s disease

Clene (CLNN) and its wholly owned subsidiary Clene Nanomedicine announced new preclinical data showing that CNM-Au8 improved key...

2M ago

CLNN

Clene presents preclinical data supporting CNM-Au8 for Parkinson’s disease

Clene (CLNN) and its wholly owned subsidiary Clene Nanomedicine announced new preclinical data showing that CNM-Au8 improved key...

2M ago

CLNN

Clene price target lowered to $48 from $83 at Canaccord

Canaccord lowered the firm’s price target on Clene (CLNN) to $48 from $83 and keeps a Buy rating...

2M ago

CLNN

CLNN FAQ

What was Clene’s price range in the past 12 months?

Clene lowest stock price was $2.28 and its highest was $11.06 in the past 12 months.

What is Clene’s market cap?

Clene’s market cap is $100.70M.

When is Clene’s upcoming earnings report date?

Clene’s upcoming earnings report date is Nov 11, 2025 which is in 11 days.

How were Clene’s earnings last quarter?

Clene released its earnings results on Aug 14, 2025. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.473 by -$0.307.

Is Clene overvalued?

According to Wall Street analysts Clene’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Clene pay dividends?

Clene does not currently pay dividends.

What is Clene’s EPS estimate?

Clene’s EPS estimate is -0.58.

How many shares outstanding does Clene have?

Clene has 10,069,970 shares outstanding.

What happened to Clene’s price movement after its last earnings report?

Clene reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.473. Following the earnings report the stock price went down -1.37%.

Which hedge fund is a major shareholder of Clene?

Currently, no hedge funds are holding shares in CLNN

Clene Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-45.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Clene

Clene Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, primarily targeting conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The company operates in the biotechnology sector, leveraging its proprietary nanotechnology platform to create drug candidates that aim to restore cellular function and improve patient outcomes. Clene’s core products include CNM-Au8, a gold nanocrystal suspension designed to enhance cellular energy metabolism and protect neuronal health.

Clene (CLNN) Earnings & Revenues

Historic Earnings Reports

CLNN Stock 12 Month Forecast

Average Price Target

$32.00

▲(220.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","13":"$13","25":"$25","37":"$37","49":"$49"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,13,25,37,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.97,10.126153846153846,13.282307692307693,16.43846153846154,19.594615384615384,22.75076923076923,25.90692307692308,29.063076923076924,32.21923076923077,35.37538461538462,38.53153846153846,41.68769230769231,44.84384615384616,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.97,8.895384615384614,10.82076923076923,12.746153846153845,14.67153846153846,16.596923076923076,18.52230769230769,20.447692307692307,22.373076923076923,24.298461538461538,26.223846153846154,28.14923076923077,30.074615384615385,{"y":32,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.97,7.972307692307692,8.974615384615385,9.976923076923077,10.97923076923077,11.981538461538461,12.983846153846155,13.986153846153847,14.98846153846154,15.990769230769232,16.993076923076924,17.995384615384616,18.997692307692308,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.11,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.31,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.49,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.39,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.97,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >